Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Leukemia Interventions: Drug: Ibrutinib; Drug: Venetoclax Sponsor: Swiss Group for Clinical Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials